Filter
363
Filtered Results: 363
Text search:
Ethiopian
Food
and
Drug
Authority
Featured
Recommendations
37
New Publications
117
Language
Document type
No document type
205
Studies & Reports
77
Guidelines
41
Strategic & Response Plan
23
Manuals
11
Training Material
2
Fact sheets
2
Situation Updates
1
Resource Platforms
1
Countries / Regions
Ethiopia
75
Global
19
Kenya
18
Africa
17
Uganda
10
Ghana
8
Nigeria
7
Zambia
7
Liberia
6
Malawi
6
Sierra Leone
5
South Africa
5
Congo, Democratic Republic of
4
Tanzania
4
Rwanda
4
Namibia
4
West and Central Africa
4
Middle East and North Africa
4
South–East Asia Region
4
Pakistan
3
Sudan
3
Lesotho
3
Latin America and the Carribbean
3
Guinea
2
South Sudan
2
Jordan
2
Syria
2
Mexico
2
Myanmar / Burma
2
East and Southern Africa
2
Western and Central Europe
2
Iran
2
Burkina Faso
1
Morocco
1
Saudi Arabia
1
Zimbabwe
1
Philippines
1
India
1
Somalia
1
Iraq
1
Afghanistan
1
Lebanon
1
Cambodia
1
Thailand
1
China
1
Indonesia
1
Bangladesh
1
Mozambique
1
Central African Republic
1
Eswatini/ Swaziland
1
North Macedonia
1
Ukraine
1
Botswana
1
Greece
1
Libya
1
Yemen
1
Eastern Europe and Central Asia
1
Venezuela
1
Palestine
1
Italy
1
Albania
1
Moldova
1
Georgia
1
Tunisia
1
Authors & Publishers
Publication Years
Category
Countries
131
Clinical Guidelines
35
Public Health
27
Women & Child Health
22
Key Resources
18
Capacity Building
7
Pharmacy & Technologies
5
Toolboxes
TB
35
HIV
33
Pharmacy
23
Mental Health
22
AMR
19
COVID-19
16
NTDs
16
Refugee
11
Planetary Health
10
Rapid Response
9
Global Health Education
8
NCDs
8
Conflict
7
Caregiver
7
Cholera
4
Disability
3
Ebola
3
Health Financing Toolbox
2
Polio
1
Natural Hazards
1
Specific Hazards
1
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above...
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, ... the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, ... the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
Participant Modules
Antimicrobial resistance (AMR) has emerged as a leading cause of death in the African region, surpassing fatalities from malaria, HIV, and TB. In response to this critical threat, the region has adopted the AMR Global Action Plan ... the African Union Framework for Antimicrobial Resistance Control 2020 – 2025, which is tailored to meet the specific needs of African nations through a coordinated approach. While most countries in the region have developed and prioritized National Action Plans (NAPs) to tackle AMR, the overall response remains inadequate given the magnitude of the threat, which endangers human, animal, environmental, aquatic, and plant health.
Africa bears a significant burden of infectious diseases, accounting for approximately 95% of malaria deaths, 70% of people living with HIV, and 25% of TB deaths globally. In 2019, AMR was linked to approximately 55,000 deaths from HIV, 30,000 from malaria, and 255,000 overall. Major drivers of AMR in the region include the overuse and misuse of antimicrobials in human and food systems, migration, suboptimal vaccination rates, and environmental contamination from hospital and pharmaceutical effluents. Additionally, there is a lack of access to quality-assured antimicrobials and diagnostics, compounded by inadequate knowledge about AMR. Unlike high-income countries, where indiscriminate antimicrobial use is the primary factor driving AMR, African countries face additional challenges, including a lack of access to clean and safe water, poor Water, Sanitation, and Hygiene (WASH) programs, inadequate infection prevention measures, and suboptimal vaccinations for preventable diseases. One in three hospitals in the region lacks clean, safe running water, and one in eight people defecate openly due to inadequate sanitation. Investments in WASH, infection prevention, and biosecurity could save approximately 700,000 lives annually.
Addressing AMR in Africa requires a comprehensive, multi-sectoral approach involving the entire society. Sustainable access to antimicrobials, including antibiotics, vaccines, and therapeutics, is crucial, as lack of access leads to more morbidity and mortality than AMR itself. Support for the region should focus on preventing infections, strengthening health and food systems, developing human resources, ensuring sustainable access to diagnostics and therapeutics, and investing in laboratory infrastructure to support surveillance and data generation.
This working paper was conceived to offer practical tips and suggestions on how to establish and sustain the multisectoral coordination needed to develop ... implement National Action Plans on AMR (NAPs). It is intended for anyone with responsibility for addressing AMR at country level. Drawing on both the published literature and the operational experience of four ‘focal countries’ (Ethiopia, Kenya, Philippines and Thailand), it summarizes lessons learned and the latest thinking on multisectoral working to achieve effective AMR action. The experience in focal countries points to a number of tools and tactics that can be used to help establish and enhance sustainable multisectoral collaboration for AMR action. These can be grouped into four categories: political commitment, resources, governance mechanisms, and practical management.
Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa
recommended
The survey aimed at evaluating the quality of selected antimalarials in six countries of sub-Saharan Africa (Cameroon, Ethiopia, Ghana, Kenya, Nigeria and the United Republic ...
This working paper was conceived to offer practical tips and suggestions on how to establish and sustain the multisectoral coordination needed to develop ... implement National Action Plans on AMR (NAPs). It is intended for anyone with responsibility for addressing AMR at country level. Drawing on both the published literature and the operational experience of four ‘focal countries’ (Ethiopia, Kenya, Philippines and Thailand), it summarizes lessons learned and the latest thinking on multisectoral working to achieve effective AMR action.
In many low- and middle-income countries, there is a wide gap between evidencebased recommendations and current practice. Treatment of major CVD risk factors remains suboptimal, ... only a minority of patients who are treated reach their target levels for blood pressure, blood sugar and blood cholesterol.
In other areas, overtreatment can occur with the use of non-evidence-based
protocols. The aim of using standard treatment protocols is to improve the quality
of clinical care, reduce clinical variability and simplify the treatment options,
particularly in primary health care. Standard treatment protocols can be developed by preparing new national treatment guidelines or by adapting or adopting international guidelines.
The Evidence-based protocols module uses hypertension and diabetes screening
and treatment as an entry point to control cardiovascular risk factors, prevent target organ damage, and reduce premature morbidity and mortality. A comprehensive risk- based approach for integrated management of hypertension, diabetes, and high cholesterol is included in the Risk-based CVD management module.
This module includes clinical practice points and sample protocols for:
1. hypertension detection and treatment
2. type 2 diabetes detection and treatment
3. identifying basic emergencies – care and referral.
HEARTS emphasizes adaptation, dissemination, and use of a standardized set of
simple clinical-management protocols, which should be drug- and dose-specific,
and include a core set of medications. The simpler the protocols and management tools, the more likely they are to be used correctly, and the higher the likelihood that a programme will achieve its goals.
Crisis Group’s Watch List identifies ten countries or regions at risk of deadly conflict or escalation thereof in 2021. In these places, early action, driven or supported by the EU and its member states, could enhance prospects for peace ... stability.
Crisis Group’s early-warning Watch List identifies up to ten countries and regions at risk of conflict or escalation of violence. In these situations, early action, driven or supported by the EU and its member states, could generate stronger prospects for peace. The Watch List 2021 includes an Introduction, detailed conflict analyses and EU-targeted recommendations on Central African Republic, Democratic Republic of Congo, Ethiopia, Iran & the Gulf, Libya, Mexico & Central America, Nagorno-Karabakh, Somalia, Thailand and Venezuela.
The objectives of the meeting were:
1. To step up the commitment of national authorities and technical and financial partners toWHO’s eliminatio...
The WHO standard: Universal access to rapid tuberculosis diagnostics sets benchmarks to achieve universal access to WHO-recommended rapid diagnostics (WRDs), increase bacteriologically confirmed tuberculosis and ... resistance detection, and reduce the time to diagnosis. WHO-recommended rapid diagnostics are highly accurate, cost-effective, reduce the time to treatment initiation, and impact patient-important outcomes.
Full eHandbook under: http://www.msh.org/resources/health-systems-in-action-an-ehandbook-for-leaders-and-managers
Effective supply management has the potential to make a powerful contribution to the reliable availability of essential medicines, whi...
A survey of prevention, testing and treatment policies and practices
Accessed: 07.11.2019
